Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof

Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof

US Patent 11365392 · Granted Jun 21, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibodies having specificity for CD38 and uses thereof2025
Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitor2024
Vaccine to pathogenic immune activation cells during infections2024
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells 2023
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof2021
Monoclonal antibodies binding to the CD160 transmembrane isoform2021
Vaccine to pathogenic immune activation cells during infections2021
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells 2020